Higher Liothyronine Use in Hypothyroidism With Psych History
Patients with a psychiatric history prior to their diagnosis of autoimmune hypothyroidism were nearly twice as likely to receive liothyronine treatment as those without such a history, with the effect being most pronounced among those with a history of affective or anxiety disorders.
METHODOLOGY:
Researchers in Sweden conducted a retrospective, population-based cohort study using national registry data to assess the association between prior psychiatric history and subsequent liothyronine use in patients with autoimmune hypothyroidism.
They analysed 353,708 adults who filled at least one prescription for thyroid hormone replacement (liothyronine or levothyroxine) between 2006 and 2020, of whom 44.8% had psychiatric morbidity before the first thyroid hormone prescription.
Among patients with a history of psychiatric morbidity, 96.7% were exposed to affective or anxiety morbidity and 8.3% had a history of psychotic disorders.
The primary endpoint was liothyronine therapy at any point during the median follow-up duration of 63.4 months for patients with prior psychiatric morbidity and 69.2 months for those without.
TAKEAWAY:
Overall, 3.6% of patients received liothyronine during the study period.
Patients with a history of psychiatric morbidity were more likely to receive liothyronine therapy than those without it (adjusted odds ratio [aOR], 1.90; P < .001).
< .001). The strongest association with liothyronine therapy was observed in patients with a history of affective and anxiety disorders (aOR, 1.91; P < .001), whereas no significant difference was found between those with a history of psychotic disorders and those without ( P = .11).
IN PRACTICE:
"This study provides empirical evidence that patients with autoimmune hypothyroidism and a history of psychiatric morbidity are more likely to receive LT3 [liothyronine]-treatment, especially among those with affective or anxiety morbidity," the authors wrote.
"This may reflect lingering symptoms that influence treatment decisions of hypothyroidism, either due to symptoms being misinterpreted as treatment-resistant hypothyroidism or actual physiological differences in thyroid disease within this group," they added.
SOURCE:
This study was led by Fredric Hedberg, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. It was published online on June 07, 2025, in The Journal of Clinical Endocrinology & Metabolism .
LIMITATIONS:
The retrospective design limited the ability to establish causal relationships. Data on thyroid hormone concentrations and treatment indications were lacking, preventing the determination of whether liothyronine prescriptions were due to laboratory abnormalities, persistent symptoms, or physician preferences. Moreover, information on interferon and immune checkpoint inhibitor therapies was unavailable.
DISCLOSURES:
This study was supported by grants from the Region Stockholm Drug and Therapeutic Committee and the Lisa and Johan Grönberg Foundation. The authors declared having no competing interests.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
10 minutes ago
- Medscape
Integrating CAR T and Bispecific Antibodies in MM Treatment
MILAN — The treatment landscape for relapsed and refractory multiple myeloma (RRMM) has shifted dramatically with the emergence of immunotherapies such as chimeric antigen receptor (CAR) T-cell therapies and bispecific antibodies (bsAbs). These novel approaches have delivered unprecedented outcomes in heavily pretreated patients. Yet determining the optimal treatment strategy remains a clinical challenge. Here at the 2025 European Hematology Association (EHA) Annual Meeting in Milan, Italy, leading experts weighed the strengths and limitations of both approaches, emphasizing that it is not a contest of superiority but a question of sequence and patient selection. Bispecific Antibodies: Off-the-Shelf Convenience With Strong Responses BsAbs work by redirecting T cells toward myeloma cells, binding simultaneously to a tumor antigen and CD3. In his presentation, Philippe Moreau, MD, head of the hematology department at the University Hospital of Nantes, France, reviewed the four agents approved in Europe: teclistamab, elranatamab, and linvoseltamab, which target beta cell maturation antigen (BCMA); and talquetamab, which targets G protein-coupled receptor class C group 5 member D (GPRC5D). These agents deliver overall response rates (ORRs) of 60%-70% in heavily pretreated patients, with median progression-free survival (PFS) of 12-18 months and overall survival (OS) of 24-30 months. Talquetamab in particular induces rapid responses within 1 month but is associated with unique toxicities — such as skin reactions, dysgeusia, and mucosal effects — related to GPRC5D expression in nonhematopoietic tissues like skin. BsAbs offer immediate treatment without the delays associated with CAR T manufacturing. They are also viable for frail patients and more broadly accessible outside of specialized centers. Toxicities, including cytokine release syndrome and infections, are generally manageable with step-up dosing and prophylactic tocilizumab. However, resistance remains a main concern. Roughly one third of patients — particularly those with high-risk cytogenetics, International Staging System stage III disease, or extramedullary disease — exhibit primary resistance. CAR T-Cell Therapy: Durable Outcomes With Earlier Use CAR T-cell therapies have redefined expectations in RRMM, particularly with ciltacabtagene autoleucel, which has achieved a median PFS of 35 months and a median OS approaching 61 months in heavily pretreated populations. Notably, recent data show that one third of patients remain progression-free at 5 years: an unprecedented milestone. 'Phase 3 trials now show improved PFS, OS, and quality of life compared to standard-of-care regimens,' said Paula Rodriguez-Otero, MD, medical coordinator of the Central Unit for Clinical Trials at the University of Navarra, Pamplona, Spain. However, CAR T therapy faces logistical hurdles, including manufacturing delays and the need for specialized infrastructure. High-risk patients with rapid progression or poor bridging therapy responses may still experience suboptimal results, but these challenges are mitigated when CAR T therapy is used earlier in the disease course, before T-cell exhaustion occurs. It's Not One or the Other Both speakers agreed that the future of MM treatment is not about choosing between CAR T and bsAbs but about defining the optimal sequence and integrating both modalities based on patient needs and disease features. BsAbs offer fast, outpatient-ready options for frail or rapidly progressing patients. CAR T therapies, though more complex, offer long remissions and potential treatment-free intervals, especially when used early. Still, Moreau cautioned, many questions remain. What is the best treatment sequence? Should clinicians switch targets — for example from BCMA to GPRC5D — or stick with the same? How should resistance mechanisms, such as antigen loss, be tackled? Can we move toward fixed-duration therapy to reduce costs? Scientific progress must also account for patient priorities. As Solène Clavreul, PhD, noted in an interview with Medscape Medical News , longer survival for myeloma patients means that quality of life is increasingly central. Clavreul is patient advocate and head of medical education and scientific engagement at Myeloma Patients Europe. 'The treatment choices should always be based on research data, but understanding patients' preferences is critical for shared decision-making,' she said. What's Next: BsAb Combinations and Trispecifics 'With 19 new drugs or combinations approved in the past two decades, we've made incredible progress,' said Jesús San Miguel Izquierdo, MD, PhD, director of clinical and translational medicine at the University of Navarra, Pamplona, Spain, in his EHA 2025 Lifetime Achievement Award lecture. Two industry-sponsored studies presented at EHA 2025 point to the next wave of innovation. RedirecTT-1: Dual-Antigen BsAb Combination The phase 2 RedirecTT-1 trial evaluated the combination of talquetamab and teclistamab in patients with extramedullary disease. 'Patients with true extramedullary disease are up to 87% less likely to respond to conventional therapy,' said Shaji Kumar, MD, consultant, professor, and researcher at the Mayo Clinic, Rochester, USA. The combination treatment in the trial yielded an ORR of 78.9% and a complete response rate of 54.4%, with a 12-month PFS rate of 61% and OS rate of 74.5%. Adverse events were not significantly higher than in monotherapy trials, and less frequent dosing (biweekly or monthly) improved tolerability. 'These results showed deep and durable responses in a population with a significant unmet need,' Kumar said. Moreau, who was not involved in the study, added, 'This could be the pivotal trial that leads to approval of the first bsAb combination.' JNJ-5322: First-in-Human Trispecific Antibody JNJ-5322, a trispecific antibody targeting both BCMA and GPRC5D, showed remarkable efficacy in BCMA/GPRC5D-naive patients in a phase 1 trial. 'Despite recent progress, we still need to reduce treatment burden and improve outcomes,' said Rakesh Popat, MD, hematologist at University College Hospital, London, UK. Among patients with triple-class exposed RRMM, the ORR was 100%, with a 70.4% complete response rate and 12-month PFS of 95%. Grade 3/4 infections occurred in 28.6% of patients, but the safety profile — including mild cytokine release syndrome — was manageable. 'JNJ-5322 demonstrated manageable safety and an ORR comparable to CAR T, with convenient, off-the-shelf, weekly dosing, with one step-up dosing to facilitate outpatient dosing,' Popat concluded. Popat, Clavreul, and Kumar reported no relevant financial relationships. Moreaureported honoraria from and advisory board memberships with Janssen, Celgene, Takeda, Amgen, AbbVie, Sanofi, Pfizer, and GSK. Rodriguez Otero reported honoraria from lectures from BMS-Celgene, J&J Innovative Medicines, Sanofi, GSK, Regeneron, and Pfizer; participation in Ad Board meetings for BMS, Janssen, Sanofi, Oncopeptides, Pfizer, Roche, Regeneron, AbbVie, AstraZeneca, H3 Biomedicine, and GSK; consultancy work for BMS-Celgene, AbbVie, Roche, J&J Innovative Medicines, and Pfizer; and research funding and travel support from Pfizer. San Miguel Izquierdo reported participation on advisory boards and consulting services, on behalf of his institution, for AbbVie, Amgen, BMS, Celgene, GSK, Haemalogix, Janssen-Cilag, Karyopharm, MSD, Novartis, Pfizer, Takeda, Regeneron, Roche, Sanofi, Secura Bio, and Gilead-Kite. The two industry-sponsored studies mentioned were funded by Johnson & Johnson.
CNN
an hour ago
- CNN
Never-before-seen footage shows sun's south pole
Solar Orbiter, a joint mission between NASA and the European Space Agency, is revealing the first-ever views of the sun's south pole. These never-before-seen images offer scientists a chance to better understand our star and its effects on Earth.
CNN
an hour ago
- CNN
Watch: First-ever images of sun's south pole
Watch: First-ever images of sun's south pole Solar Orbiter, a joint mission between NASA and the European Space Agency, is revealing the first-ever views of the sun's south pole. These never-before-seen images offer scientists a chance to better understand our star and its effects on Earth. 01:30 - Source: CNN Vertical Trending Now 14 videos Watch: First-ever images of sun's south pole Solar Orbiter, a joint mission between NASA and the European Space Agency, is revealing the first-ever views of the sun's south pole. These never-before-seen images offer scientists a chance to better understand our star and its effects on Earth. 01:30 - Source: CNN The NHL Stanley Cup's perfect imperfections The Stanley Cup is one of the most iconic trophies in all of sports, but one of the reasons the NHL's championship trophy is so lionized is its perfect imperfections. CNN's Coy Wire spoke to The Keeper of the Cup Howie Borrow for a tour of some of the trophy's character-building bloopers. 01:02 - Source: CNN Storm chaser captures 'unprecedented' view of monster hailstones falling from sky Storm chaser and research scientist Sean Waugh has documented softball sized (or greater) hailstones in freefall with an ultra-high-tech camera mounted on a retrofitted research vehicle. The goal – to study and better understand what makes gigantic hail form, and how to better detect it and ultimately improve severe weather warnings. Sean speaks with CNN Meteorologist Derek Van Dam while on the road, capturing imagery of this very impactful and expensive natural phenomenon. (edited) 01:47 - Source: CNN Flash flood destroys apartment building An apartment building in West Virginia partially collapsed as flash floods hit the area. The governor's office said at least five people are dead and four people remain missing following the floods. 00:31 - Source: CNN After talking to hundreds of dads, this podcaster shares his two biggest lessons Dr. John Delony speaks to millions of listeners on his popular podcast about mental health, family and relationships. As a therapist, he's used to offering advice to struggling fathers, but we asked him about the biggest lessons he's learned as a dad. 01:32 - Source: CNN Rare deep-sea squid filmed alive for first time Scientists have captured the first-ever footage of the elusive Gonatus antarcticus squid alive in its deep-sea habitat. CNN's Jeremy Roth describes the rare encounter. For more on this story, visit 01:12 - Source: CNN Trump draws boos and cheers at Kennedy Center President Donald Trump drew charged reactions of both admiration and ire at the Kennedy Center's opening night of "Les Misérables." 00:29 - Source: CNN The many adventures of the Stanley Cup Winner's of the NHL's Stanley Cup each get to take the cup for a day and do whatever they want with it. CNN's Coy Wire recounts some of the Cup's wildest days out. 00:43 - Source: CNN BTS members discharged from South Korean military One of the world's biggest boybands could soon be making a comeback with six out of seven members of K-Pop supergroup BTS now discharged from South Korea's mandatory military service. The band plans to reunite at some point later this year. 00:47 - Source: CNN Combs requests mistrial for a second time CNN's Elizabeth Wagmeister explains that Sean "Diddy" Combs' defense team requested a mistrial for a second time, which was denied. Combs' team accused the prosecution of presenting false testimony from Bryana Bongolan, a friend of Cassie Ventura's, who testified that Combs dangled her over a balcony. 01:26 - Source: CNN Tennessee sheriff's office airlifts escaped zebra to safety DEK: A zebra, that escaped from its owner in Christiana, Tennessee was captured on Sunday and airlifted to safety by the local sheriff's office. The animal, named Ed, had been reported missing just a day after he was acquired by its owners in Rutherford County. They have since been reunited. 00:35 - Source: CNN Jamie Foxx breaks down during BET Awards acceptance speech Jamie Foxx was overcome with emotion while accepting the Ultimate Icon Award at the BET Awards. He reflected on his 2023 health scare. 00:45 - Source: CNN See what's coming to your iPhone and other Apple devices Apple announced major software updates at its annual Worldwide Developers Conference. Most of the new features won't reach users' devices for a few months when OS 26 releases this fall. 01:49 - Source: CNN Coco Gauff reacts to winning the French Open Coco Gauff claimed her second career grand slam singles title, defeating world No. 1 Aryna Sabalenka in the French Open women's final. 00:46 - Source: CNN
